Depresyonda Sürdürüm Tedavisi
Özet
Depresyon, iyileşme sonrasında yüksek yineleme riski taşıyan, kronikleşebilen bir rahatsızlık olduğundan, tedavisinde sadece akut iyileşmeyi değil, uzun vadeli sürdürümü de hedeflemek kritik bir öneme sahiptir. Araştırmalar, majör depresyon geçiren hastaların çoğunda birden fazla atak görüldüğünü ve geçirilen atak sayısı arttıkça yeni bir epizot riskinin katlanarak yükseldiğini ortaya koymaktadır. Sürdürüm tedavisinin temel amacı bu yinelemeleri önlemek olup; farmakoterapi, psikoeğitim ve psikoterapi süreçlerinin entegrasyonuyla yürütülmektedir. Bu süreçte hastaların uyumunu artırmak adına yan etki profili düşük ajanların seçilmesi ve akut dönemde başarı sağlanan ilaç dozunun korunması önerilmektedir. Tedavinin sonlandırılması aşamasında ise grip benzeri semptomlar, uykusuzluk ve anksiyete gibi geri çekilme belirtilerini en aza indirmek ve akut nüks riskini engellemek için, ilaç dozunun 4-6 aya yayılan kademeli bir programla azaltılması ve hastanın ilk altı ay boyunca yakından takip edilmesi gerekmektedir.
Depression is a recurrent and chronic illness with a high rate of relapse after recovery; therefore, long-term maintenance rather than just acute remission is crucial in its management. Research indicates that the majority of patients experience multiple episodes, and the risk of recurrence escalates with each subsequent episode. The primary goal of maintenance therapy is to prevent these relapses, utilizing a combination of pharmacotherapy, psychoeducation, and psychotherapy. To optimize patient adherence during this phase, selecting medications with low side-effect profiles and sustaining the effective acute-phase dosage is highly recommended. When discontinuing treatment, to minimize withdrawal symptoms such as flu-like signs, insomnia, and anxiety, and to prevent acute relapse, the medication must be tapered gradually over a period of 4 to 6 months, coupled with close clinical monitoring especially during the initial six months.
Referanslar
Kora K. (2008). Depresyonda Koruyucu Sağaltım. Olcay Yazıcı, E. Timuçin Oral, Simavi Vahip (Ed.), Depresyon Sağaltım Kılavuzu Kaynak Kitabı içinde (s. 153-159). Ankara: BAYT Bilimsel Araştırmalar Basın Yayın ve Tanıtım Ltd. Şti.
Karakuş G, Tamam L. (2010). Depresyon Tedavisinde Temel İlkeler. Nevzat Yüksel (Ed.), Temel Psikofarmakoloji içinde (s. 710-718). Ankara: BAYT Bilimsel Araştırmalar Basın Yayın ve Tanıtım Ltd. Şti.
Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry. 2005;66 (suppl 8): 5-12.
Hardeveld F, Spijker J, de Graaf R, et al. Recurrence of major depressive disorder across different treatment settings: results from the NESDA study. J Affect Disord. 2013;147: 225-231
Lam RW, McIntosh D, Wang J, et al. CANMAT 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care. Can J Psychiary. 2016; 61(9): 510-23.
Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010;40: 41-50.
van der Voort TY, Seldenrijk A, van Meijel B, et al. Functional versus syndromal recovery in patients with major depressive disorder and bipolar disorder. J Clin Psychiatry. 2015;76: e809-e814.
Kılıç F, Atay İM, Kuzugüdenlioğlu D. (2021). Ağır Şiddette Depresyon Sağaltımı. Kürşat Altınbaş, Fisun Akdeniz, Ali Bozkurt (Ed.), Depresyon Sağaltım Kitabı içinde (s. 71-84). Ankara: BAYT Bilimsel Araştırmalar Basın Yayın ve Tanıtım Ltd. Şti
Bockting CL, Hollon SD, Jarrett RB, et al. A lifetime approach to major depressive disorder: the contributions of psychological interventions in preventing relapse and recurrence. Clin Psychol Rev. 2015;41: 16-26.
Sim K, Lau WK, Sim J, et al. Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials. Int J Neuropsychopharmacol. 2015;19: 1-13.
Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBF) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry. 2002;3(2): 69-86.
Kupfer DJ. Management of recurrent depression. J Clin Psychiatry. 1993;54(Suppl. 2): 29-33.
Borges S, Chen YF, Laughren TP, et al. Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration. J Clin Psychiatry. 2014;75: 205-214.
Kriston L, von Wolff A, Westphal A, et al. Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis. Depress Anxiety. 2014;31: 621-630.
von Wolff A, Ho¨lzel LP, Westphal A, et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord. 2013;144: 7-15
Keitner GI, Mansfield AK. Management of treatment-resistant depression. Psychiatr Clin North Am. 2012;35: 249-265.
Franchini L, Rossini D, Bongiorno F, et al. Will a second prophylactic treatment with a higher dosage of the same antidepressant either prevent or delay new depressive episodes? Psychiatry Res. 2000;96: 81-85.
Keller MB. Rationale and options for the long-term treatment of depression. Human Psychopharm. 2002;17: 43-46.
Paykel ES. Continuation and maintenance therapy in depression. Br Med Bull. 2001;57: 145-159.
Rush AJ. (2005). Mood disorders: Treatment of depression. BJ Sadock, VA Sadock (Eds). Comprehensive Textbook of Psychiatry (8th ed, pp. 1659-1660). Philadelphia: Lippincott Williams&Wilkins.
Shelton, CI. Long-term management of major depressive disorder: Are differences among antidepressant treatments meaningful? J Clin Psychiatry. 2004;65(Suppl.17): 29-33.
Frank E, Kupfer DJ, Perel JM, et al. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord. 1993;27: 139-145.
Franchini L, Gasperini M, Perez J, et al. Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. J Clin Psychiatry. 1998;59(5): 229-232.
Thase ME, Jacobsen PL, Hanson E, et al. Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study. Journal of Affective Disorders 303. 2022;123-130.
van den Broek, Birkenhager TK, Mulder PG, et al. Imipramine is effective in preventing relapse in electroconvulsive therapy-responsive depressed inpatients with prior pharmacotherapy treatment failure: a randomized, placebo-controlled trial. J Clin Psychiatry. 2006;67(2): 263-8.
Jelovac A, Kolshus E, McLoughlin DM. Relapse following a successful electroconvulsive therapy for major depression: a meta analysis. Neuropsychopharmacology. 2013;38: 2467-74.
Rothschild AJ. Challenges in the treatment of major depressive disorder with psychotic features. Schizophr Bull. 2013; 39(4): 787–96.
Dubovsky SL, Ghosh BM, Serotte JC, et al. Psychotic Depression: Diagnosis, Differential Diagnosis, and Treatment. Psychother Psychosom. 2021;90: 160–177.
Rasmussen KG. Lithium for post-electroconvulsive therapy depressive relapse prevention: a consideration of the evidence. J ECT. 2015;31(2): 87-90.
Cipriani A, Smith K, Burgess S, et al. Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Syst Rev. 2006;18(4): CD003492.
Bauer M, Severus E, Köhler S, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 2015;16(2): 76–95.
Abou‑Saleh et al. Lithium in the episode and suicide prophylaxis and in augmenting strategies in patients with unipolar depression. Int J Bipolar Disord. 2017; 5:11.
Olfson M, Marcus SC, Tedeschi M, et al. Continuity of antidepressant treatment for adults with depression in the United States. American Journal of Psychiatry. 2006;163: 101-108.
Hunot VM, Horne R, Leese MN, et al. A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences. Primary Care Companion to the Journal of Clinical Psychiatry. 2007;9: 91–99.
Diniz BS, Reynolds CF. Major Depressive Disorder in Older Adults: Benefits and Hazards of Prolonged Treatment. Drugs Aging. 2014; 31(9): 661–669.
Berwian MI, Walter H, Seifritz E, et al. Predicting relapse after antidepressant withdrawal-a systematic review. Psychological Medicine. 2017;47: 426-437.
Trivedi MH, Dunner DL, Kornstein SG, et al. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010;126:420-429.
Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: III. Pharmacotherapy. J Affect Disord. 2009;117(Suppl 1): 26-43.
Kennedy SH, Lam RW, McIntrye RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiary. 2016; 61(9): 540-60.
Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists (RANZCP) clinical practice guidelines for mood disorders. Aust N J Z Psychiatry. 2015;49(12): 1087-206.
Kupfer DJ, Frank E, Perel JM, et al. Five year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1992;49: 769-773.
Rush AJ, Kupfer DJ. (2001). Strategies and tactics in the treatment of depression. GO Gabbard (Ed). Treatment of Psychiatric Disorders (3rd ed, pp. 1417-1439). Washington DC: American Psychiatric Publishing Inc.
Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361: 653–61.
Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44: 77–87.
Fava GA, Gatti A, Belaise C, et al. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84: 72-81.
Berber MJ. FINISH: remembering the discontinuation syndrome. Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, and Hyperarousal (anxiety/agitation). J Clin Psychiatry. 1998;59: 255.
Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry. 2010;167: 934-41.
Guidi J, Tomba E and Fava GA. The sequential integration of pharmacotherapy and psychotherapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature. Am J Psychiatry. 2016;173: 128–137.
